arbekacin has been researched along with Infections, Pseudomonas in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.69) | 18.7374 |
| 1990's | 7 (53.85) | 18.2507 |
| 2000's | 2 (15.38) | 29.6817 |
| 2010's | 3 (23.08) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adams, J; de Oliveira Garcia, D; Doi, Y; Paterson, DL | 1 |
| Hasegawa, H; Izumikawa, K; Kaku, N; Kosai, K; Miyazaki, T; Morinaga, Y; Mukae, H; Takeda, K; Uno, N; Yanagihara, K | 1 |
| Araoka, H; Baba, M; Ishii, Y; Mitsuda, T; Mori, S; Moriya, K; Nakamori, Y; Oguri, T; Ohmagari, N; Oishi, T; Okuzumi, K; Tateda, K; Yamaguchi, K; Yoneyama, A | 1 |
| Kirikae, T; Miyoshi-Akiyama, T; Shimada, K; Shimojima, M; Tada, T | 1 |
| Hikida, M; Kawabata, T; Maebashi, K; Niida, M; Sakakibara, S; Takata, T | 1 |
| Tanaka, Y | 1 |
| Hamada, T; Harada, R; Hata, E; Miyamoto, H; Sakao, Y | 1 |
| Hayashi, I; Ichiki, M; Ishikawa, T; Karato, A; Niida, M; Ogawa, M; Sakurai, M; Sekine, I; Shiotani, J; Yoshida, T | 1 |
| Goto, S; Sugano, T; Takada, T; Takase, Y; Tsuji, A; Yamaguchi, K; Yoshida, T | 1 |
| Goto, A; Hasegawa, S; Irokawa, M; Ishida, H; Iwata, S; Nakai, T; Otsuka, M; Sawahata, T; Shinohara, Y; Yoshizawa, Y | 1 |
| Fujioka, Y; Houjou, S; Iida-Tanaka, K; Miki, S; Nakamura, Y; Takahara, J; Takahashi, T; Tamura, T; Tanaka, T; Yamanoi, Y | 1 |
| Arakawa, K; Hattori, F; Hoshino, H; Kono, K; Minamikawa, H; Miyake, S; Sato, M; Takeda, S; Tanaka, H; Tatara, I | 1 |
| Watanabe, A | 1 |
3 trial(s) available for arbekacin and Infections, Pseudomonas
| Article | Year |
|---|---|
[Laboratory and clinical studies on combined effects of fosfomycin plus sulbactam/cefoperazone for mixed infections of MRSA and Pseudomonas aeruginosa].
Topics: Adult; Aged; Aged, 80 and over; Aminoglycosides; Anti-Bacterial Agents; Bacterial Infections; Cefoperazone; Dibekacin; Drug Therapy, Combination; Female; Fosfomycin; Humans; Male; Methicillin Resistance; Middle Aged; Pseudomonas Infections; Staphylococcal Infections; Staphylococcus aureus; Sulbactam; Vancomycin | 1994 |
[Efficacy of combination therapy against MRSA in Ibaraki Prefecture].
Topics: Adolescent; Adult; Aged; Aminoglycosides; Anti-Bacterial Agents; Child; Child, Preschool; Dibekacin; Drug Therapy, Combination; Female; Fosfomycin; Humans; Infant; Japan; Lactams; Male; Methicillin Resistance; Middle Aged; Pseudomonas Infections; Staphylococcal Infections; Staphylococcus aureus | 1994 |
[Staggered intensive chemotherapy using arbekacin, fosfomycin and ceftazidime on polymicrobial infections involving MRSA].
Topics: Aged; Aged, 80 and over; Aminoglycosides; Anti-Bacterial Agents; Bacterial Infections; Ceftazidime; Dibekacin; Drug Administration Schedule; Drug Therapy, Combination; Female; Fosfomycin; Humans; Male; Methicillin Resistance; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Staphylococcal Infections; Staphylococcus aureus | 1994 |
10 other study(ies) available for arbekacin and Infections, Pseudomonas
| Article | Year |
|---|---|
Coproduction of novel 16S rRNA methylase RmtD and metallo-beta-lactamase SPM-1 in a panresistant Pseudomonas aeruginosa isolate from Brazil.
Topics: Amino Acid Sequence; Aminoglycosides; beta-Lactamases; Brazil; Carbapenems; Cloning, Molecular; Drug Resistance, Multiple, Bacterial; Methyltransferases; Microbial Sensitivity Tests; Molecular Sequence Data; Plasmids; Pseudomonas aeruginosa; Pseudomonas Infections | 2007 |
Efficacy and pharmacokinetics of ME1100, a novel optimized formulation of arbekacin for inhalation, compared with amikacin in a murine model of ventilator-associated pneumonia caused by Pseudomonas aeruginosa.
Topics: Administration, Inhalation; Amikacin; Animals; Anti-Bacterial Agents; Dibekacin; Disease Models, Animal; Drug Compounding; Lung; Mice; Microbial Sensitivity Tests; Pneumonia, Ventilator-Associated; Pseudomonas aeruginosa; Pseudomonas Infections | 2017 |
In vitro combination effects of aztreonam and aminoglycoside against multidrug-resistant Pseudomonas aeruginosa in Japan.
Topics: Amikacin; Anti-Bacterial Agents; Aztreonam; Dibekacin; Dose-Response Relationship, Drug; Drug Combinations; Drug Evaluation, Preclinical; Drug Resistance, Multiple, Bacterial; Gentamicins; Humans; Japan; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Statistics, Nonparametric | 2012 |
novel 6'-n-aminoglycoside acetyltransferase AAC(6')-Iaj from a clinical isolate of Pseudomonas aeruginosa.
Topics: Acetylation; Acetyltransferases; Amino Acid Sequence; Aminoglycosides; Anti-Bacterial Agents; Bacterial Proteins; Chromatography, Thin Layer; Dibekacin; Drug Resistance, Multiple, Bacterial; Escherichia coli; Gentamicins; Humans; Integrons; Microbial Sensitivity Tests; Molecular Sequence Data; Plasmids; Pseudomonas aeruginosa; Pseudomonas Infections; Recombinant Proteins; Sequence Alignment; Sequence Homology, Amino Acid; Substrate Specificity | 2013 |
[Combined effects of arbekacin with biapenem against in vitro and in vivo model of a mixture of MRSA and Pseudomonas aeruginosa].
Topics: Aminoglycosides; Animals; Anti-Infective Agents; Dibekacin; Disease Models, Animal; Drug Combinations; Drug Resistance, Bacterial; Drug Therapy, Combination; Male; Methicillin Resistance; Mice; Mice, Inbred ICR; Pseudomonas aeruginosa; Pseudomonas Infections; Staphylococcal Infections; Staphylococcus aureus; Thienamycins | 2004 |
Effects of habekacin, a novel aminoglycoside antibiotic, on experimental corneal ulceration due to Pseudomonas aeruginosa.
Topics: Administration, Topical; Aminoglycosides; Animals; Anti-Bacterial Agents; Corneal Ulcer; Dibekacin; Injections, Intramuscular; Keratitis; Male; Mice; Pseudomonas Infections | 1981 |
[Combination therapy with arbekacin and fosfomycin against postoperative severe mixed-pneumonia of MRSA in primary lung cancer patients].
Topics: Aged; Aminoglycosides; Anti-Bacterial Agents; Dibekacin; Drug Therapy, Combination; Fosfomycin; Humans; Immunocompromised Host; Lactams; Lung Neoplasms; Male; Methicillin Resistance; Middle Aged; Pneumonia, Bacterial; Postoperative Complications; Pseudomonas Infections; Staphylococcal Infections; Staphylococcus aureus | 1995 |
[Evaluation of bactericidal activity of arbekacin in mixed culture with MRSA and Pseudomonas aeruginosa using an in vitro pharmacokinetic simulation system].
Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; Computer Simulation; Dibekacin; Gentamicins; Male; Methicillin Resistance; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Netilmicin; Pseudomonas aeruginosa; Pseudomonas Infections; Staphylococcal Infections; Staphylococcus aureus; Vancomycin | 1994 |
Combined therapy with arbekacin and fosfomycin for methicillin-resistant Staphylococcus aureus infections.
Topics: Aminoglycosides; Anti-Bacterial Agents; Dibekacin; Drug Therapy, Combination; Fosfomycin; Humans; Methicillin Resistance; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Staphylococcal Infections; Staphylococcus aureus; Superinfection | 1994 |
[Respiratory tract infections in the elderly, advances and limitations in the diagnosis and treatment].
Topics: Aged; Aminoglycosides; Anti-Bacterial Agents; Cross Infection; Cytomegalovirus Infections; Dibekacin; Erythromycin; Humans; Methicillin Resistance; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolones; Respiratory Tract Infections; Staphylococcal Infections; Vancomycin | 1992 |